Compare Becton Dickinson and Co (BDX) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Freeport-McMoRan Inc — how do they compare? Becton Dickinson and Co trades at $154.97 (market cap $41.51B), while Freeport-McMoRan Inc trades at $60.95 (market cap $89.06B). The key difference: Freeport-McMoRan Inc is far larger — about 2.1× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | FCX | |
|---|---|---|
Market Cap | $41.51B | $89.06B |
Sector | Health | Basic Materials |
52-Week High | $185.39 | $71.73 |
52-Week Low | $135.49 | $35.34 |
Enterprise Value | $57.97B | $95.72B |
Dividend Yield | 2.79% | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
FCX trades at $59.98, down 2.51% today, with a bearish technical signal but strong fundamentals. Recent earnings beats and a 10.34% net income margin highlight operational strength. The stock faces near-term resistance at $61, with support at $59. Analysts maintain a $72.94 consensus target, reflecting 22% upside potential. Copper demand growth and expansion projects support long-term prospects.
Outlook remains positive driven by copper's structural supply-demand imbalance and FCX's cost leadership. Risks include commodity price volatility and execution challenges in new projects. Institutional sentiment is bullish with 59% buy ratings, though technical indicators suggest near-term consolidation. The dividend yield of 0.25% provides modest income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
